Liquid biopsy in the era of immune-oncology. Is it ready for prime-time use for cancer patients?, Ann. Oncol, 2019. ,
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, N. Engl. J. Med, vol.378, pp.2078-2092, 2018. ,
Nivolumab in Previously Untreated Melanoma without BRAF Mutation, N. Engl. J. Med, vol.372, pp.320-330, 2015. ,
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC, Nat. Rev. Clin. Oncol, vol.16, pp.341-355, 2019. ,
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer, JAMA Oncol, vol.2, pp.46-54, 2016. ,
PD-L1 biomarker testing for non-small cell lung cancer: Truth or fiction?, J Immunother Cancer. J. Immunother. Cancer, vol.4, 2016. ,
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1), Proc. Natl. Acad. Sci, vol.115, pp.10119-10126, 2018. ,
PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non-Small Cell Lung Cancer Patients with Malignant Pleural Effusion, J. Thorac. Oncol, vol.13, pp.447-453, 2018. ,
Low PD-1 Expression in Cytotoxic CD8 + Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value, Clin. Cancer. Res, vol.24, pp.407-419, 2018. ,
Biomarkers for Immune Checkpoint Inhibitors in Melanoma, Front Oncol, 2018. ,
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers, Mol. Cancer Ther, vol.16, pp.2598-2608, 2017. ,
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, vol.348, pp.124-128, 2015. ,
Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma, Nat. Commun, vol.8, pp.1-10, 2017. ,
Tumor mutational load predicts survival after immunotherapy across multiple cancer types, Nat. Genet, vol.51, pp.202-206, 2019. ,
Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors, Proc. Natl. Acad. Sci, vol.113, pp.7769-7777, 2016. ,
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden, N. Engl. J. Med, vol.378, pp.2093-2104, 2018. ,
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers, J. Clin. Oncol, vol.37, pp.992-1000, 2019. ,
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer, N. Engl. J. Med, vol.376, pp.2415-2426, 2017. ,
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer, Cancer Cell, vol.33, pp.843-852, 2018. ,
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden, Genome Med, vol.9, pp.1-14, 2017. ,
A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the Oncomine Tumor Mutation Load Assay, Transl. Lung Cancer Res, vol.7, pp.616-630, 2018. ,
Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing, J. Clin. Oncol, vol.36, pp.633-641, 2018. ,
Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice, Oncotarget, vol.6, pp.34221-34227, 2015. ,
Implementing tumor mutational burden (TMB) analysis in routine diagnostics-A primer for molecular pathologists and clinicians, Transl. Lung Cancer Res, vol.7, pp.703-715, 2018. ,
Optimizing panel-based tumor mutational burden (TMB) measurement, Ann. Oncol, 2019. ,
Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: Getting ready for prime-time or not? Transl, Lung Cancer Res, vol.7, pp.631-638, 2018. ,
Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic, Ann. Oncol, vol.30, pp.44-56, 2019. ,
Tumor mutational burden analysis of 2,000 Japanese cancer genomes using whole exome and targeted gene panel sequencing, Biomed. Res, vol.39, pp.159-167, 2018. ,
Improvement of tumor mutation burden measurement by removal of deaminated bases in FFPE DNA, Proceedings of the AACR Annual Meeting, 2019. ,
, Abstract 1701, p.1701
The efficacy of uracil DNA glycosylase pretreatment in amplicon-based massively parallel sequencing with DNA extracted from archived formalin-fixed paraffin-embedded esophageal cancer tissues, Cancer Genet, vol.208, pp.415-427, 2015. ,
Repair of DNA damage caused by cytosine deamination in mitochondrial DNA of forensic case samples, Forensic Sci. Int. Genet, vol.34, pp.257-264, 2018. ,
Evaluation of Hybridization Capture Versus Amplicon-Based Methods for Whole-Exome Sequencing, Hum. Mutat, vol.36, pp.903-914, 2015. ,
Spatial and temporal heterogeneity of panel-based tumor mutational burden (TMB) in pulmonary adenocarcinoma: Separating biology from technical artifacts, J. Thorac. Oncol, 2019. ,
Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: In silico and real-life analysis of three larger gene panels, Int. J. Cancer, vol.144, pp.2303-2312, 2019. ,
Designing gene panels for tumor mutational burden estimation: The need to shift from 'correlation' to 'accuracy, J. Immunother. Cancer, vol.7, p.206, 2019. ,
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma -results of a prospective biomarker study, J. Immunother. Cancer, vol.7, p.180, 2019. ,
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma, Cell, vol.165, pp.35-44, 2016. ,
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), Eur. J. Cancer, vol.45, pp.228-247, 2009. ,
Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer, Ann. Oncol, vol.29, pp.193-199, 2018. ,
PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1 + and CD8 + tumor-infiltrating T cells and outcome, Mod. Pathol, vol.29, pp.1552-1564, 2016. ,
Scikit-learn: Machine Learning in Python, J. Mach. Learn Res, vol.12, pp.2825-2830, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00650905